Tazobactam

Basic Information

CAS ID: 89786-04-9
Molecular Formula: C10H12N4O5S
Molecular Weight: 300.3 g/mol
Monoisotopic Mass: 300.0528 g/mol
Class: Small Molecule
Natural Product: No
Other Names: Tazocillin | TAZOBACTAM SODIUM | TAZOBACTAM | YTR-830H | CL 307,579 | CL 298,741
Analysis: Drug repositioning mechanism analysis

N N N N O S O O O OH

Compound Structure and Identifier

InChI: InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1 See All
InChI Key: LPQZKKCYTLCDGQ-WEDXCCLWSA-N
Smiles: C[C@]1(Cn2ccnn2)[C@@H](N3[C@@H](CC3=O)S1(=O)=O)C(=O)O See All
Molfile: Download

Related Target

Related Fibrosis Property

Reference Record 1

PubMed ID 17485505 Target ID
Uniprot ID Name
Model human Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Reference Record 2

PubMed ID 27550351 Target ID
Uniprot ID Name
Model human Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Trial Record 1

ClinicalTrial ID NCT01694069 Disease Cystic fibrosis
Phase Phase 4 Status Terminated
First Received September 26, 2012 Last Verified March 18, 2014
Sponsor West Virginia University

Trial Record 2

ClinicalTrial ID NCT02840136 Disease Cystic fibrosis
Phase Not Applicable Status Suspended
First Received July 21, 2016 Last Verified June 13, 2018
Sponsor University Ghent

Trial Record 3

ClinicalTrial ID NCT02421120 Disease Cystic fibrosis
Phase Phase 4 Status Completed
First Received April 20, 2015 Last Verified March 19, 2018
Sponsor Joseph Kuti

Trial Record 4

ClinicalTrial ID NCT00153634 Disease Cystic fibrosis
Phase Not Applicable Status Completed
First Received September 12, 2005 Last Verified March 13, 2008
Sponsor Seattle Children's Hospital

Trial Record 5

ClinicalTrial ID NCT01983787 Disease Cystic fibrosis
Phase Status Completed
First Received November 14, 2013 Last Verified December 11, 2015
Sponsor University of Aarhus

Related Link

PubChem: 123630
ChEMBL: CHEMBL404